论文部分内容阅读
目的探讨肾移植术后环孢素A血药浓度监测在临床中应用价值及意义。方法对26例肾移植术后患者采用三联免疫抑制用药方案,并对其进行不同时间的CsA血药浓度监测,同时对药物的不良反应进行临床总结。结果肾移植术后不同时间的平均CsA血药浓度监测示:<1月为(341±53.7)ng/ml,1月为(309±49.4)ng/ml,3月为(286±46.1)ng/ml,6月为(237±41.5)ng/ml,1年为(218±39.3)ng/ml,>1年为(164±37.8)ng/ml。26例肾移植术后患者,出现急性排斥反应5例占19.23%。结论肾移植术后实施CsA用药个体化方案,监测CsA血药浓度,及时调整药物剂量,是指导临床医师调整给药方案重要依据。
Objective To investigate the clinical value and significance of cyclosporin A blood concentration monitoring after renal transplantation. Methods Twenty - six patients undergoing renal transplantation were treated with triple immunosuppressive regimen and CsA concentration monitoring was performed at different times. At the same time, clinical adverse reactions were summarized. Results The mean CsA concentration monitoring at different time points after renal transplantation was (341 ± 53.7) ng / ml in January, (309 ± 49.4) ng / ml in January and (286 ± 46.1) ng in March / ml, (237 ± 41.5) ng / ml in June, (218 ± 39.3) ng / ml in one year and (164 ± 37.8) ng / ml in> 1 year. 26 cases of renal transplantation patients, acute rejection occurred in 5 cases accounted for 19.23%. Conclusion Individualized CsA regimen after renal transplantation, monitoring of serum CsA concentration and timely adjustment of drug dosage are important guidelines for clinicians to adjust the dosage regimen.